| scholarly article | Q13442814 |
| P50 | author | Jiří Vencovský | Q42956790 |
| P2093 | author name string | Ernest Choy | |
| Niti Goel | |||
| Robert Valente | |||
| Rieke Alten | |||
| Owen Davies | |||
| Brenda Vanlunen | |||
| Frank McKenna | |||
| Hans-Detlev Stahl | |||
| P433 | issue | 7 | |
| P304 | page(s) | 1226-1234 | |
| P577 | publication date | 2012-02-16 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. | |
| P478 | volume | 51 |
| Q26471538 | Biologic interventions for fatigue in rheumatoid arthritis |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q24193535 | Certolizumab pegol (CDP870) for rheumatoid arthritis in adults |
| Q47836056 | Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. |
| Q38344194 | Certolizumab pegol for the treatment of psoriatic arthritis |
| Q55000881 | Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. |
| Q38198118 | Certolizumab pegol in rheumatoid arthritis: current update |
| Q38075801 | Certolizumab pegol: a review of its use in the management of rheumatoid arthritis |
| Q28547851 | Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis |
| Q38155217 | Drug safety evaluation of certolizumab pegol |
| Q51209335 | Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice |
| Q38200927 | Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice |
| Q38212142 | Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison |
| Q57330038 | Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis |
| Q61453693 | Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis |
| Q38176549 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis |
| Q26798357 | Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice |
| Q33725553 | Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q33667897 | Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population |
| Q30240183 | Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. |
| Q30240212 | Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis |
| Q35758262 | Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. |
| Q37587412 | Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis |
| Q38129037 | The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. |
| Q35086227 | Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis |
| Q34818636 | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| Q39237760 | What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors |
Search more.